MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib
Clinical trial NCT06075225 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06075225
- Sponsor
- Sichuan University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-01
- Primary completion
- 2024-09-30
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.